Remission rates in the overall population were higher for levomilnacipran ER versus placebo ( 27.7 % versus 21.5 % ; P < .05 ) ; notably high remission rates were seen in patients with baseline MADRS score < 30 ( 48.8 % versus 28.9 % ; P < .001 ) .